brilinta

Generic: ticagrelor

Labeler: astrazeneca pharmaceuticals lp
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name brilinta
Generic Name ticagrelor
Labeler astrazeneca pharmaceuticals lp
Dosage Form TABLET
Routes
ORAL
Active Ingredients

ticagrelor 60 mg/1

Manufacturer
AstraZeneca Pharmaceuticals LP

Identifiers & Regulatory

Product NDC 0186-0776
Product ID 0186-0776_c664bf3d-f861-4588-afbf-c3c52f1ae430
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA022433
Listing Expiration 2026-12-31
Marketing Start 2015-09-04

Pharmacologic Class

Established (EPC)
p2y12 platelet inhibitor [epc]
Mechanism of Action
p2y12 receptor antagonists [moa] cytochrome p450 3a4 inhibitors [moa] p-glycoprotein inhibitors [moa]
Physiologic Effect
decreased platelet aggregation [pe]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 01860776
Hyphenated Format 0186-0776

Supplemental Identifiers

RxCUI
1116635 1116639 1666332 1666334
UNII
GLH0314RVC
NUI
N0000182142 N0000008832 N0000182143 N0000182141 N0000185503

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name brilinta (source: ndc)
Generic Name ticagrelor (source: ndc)
Application Number NDA022433 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 60 mg/1
source: ndc
Packaging
  • 60 TABLET in 1 BOTTLE (0186-0776-60)
source: ndc

Packages (1)

0186-0776-60 60 TABLET in 1 BOTTLE (0186-0776-60)

Ingredients (1)

ticagrelor (60 mg/1)

Linked Drug Pages (1)

BRILINTA ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "c664bf3d-f861-4588-afbf-c3c52f1ae430", "openfda": {"nui": ["N0000182142", "N0000008832", "N0000182143", "N0000182141", "N0000185503"], "unii": ["GLH0314RVC"], "rxcui": ["1116635", "1116639", "1666332", "1666334"], "spl_set_id": ["f7b3f443-e83d-4bf2-0e96-023448fed9a8"], "pharm_class_pe": ["Decreased Platelet Aggregation [PE]"], "pharm_class_epc": ["P2Y12 Platelet Inhibitor [EPC]"], "pharm_class_moa": ["P2Y12 Receptor Antagonists [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "manufacturer_name": ["AstraZeneca Pharmaceuticals LP"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET in 1 BOTTLE (0186-0776-60)", "package_ndc": "0186-0776-60", "marketing_start_date": "20150904"}], "brand_name": "BRILINTA", "product_id": "0186-0776_c664bf3d-f861-4588-afbf-c3c52f1ae430", "dosage_form": "TABLET", "pharm_class": ["Cytochrome P450 3A4 Inhibitors [MoA]", "Decreased Platelet Aggregation [PE]", "P-Glycoprotein Inhibitors [MoA]", "P2Y12 Platelet Inhibitor [EPC]", "P2Y12 Receptor Antagonists [MoA]"], "product_ndc": "0186-0776", "generic_name": "Ticagrelor", "labeler_name": "AstraZeneca Pharmaceuticals LP", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "BRILINTA", "active_ingredients": [{"name": "TICAGRELOR", "strength": "60 mg/1"}], "application_number": "NDA022433", "marketing_category": "NDA", "marketing_start_date": "20150904", "listing_expiration_date": "20261231"}